Navigation Links
Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
Date:11/28/2007

ces.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995

With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Aida Pharmaceuticals could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Aida Pharmaceuticals, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Aida Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2008)...ceived positive results of nine month,PAINT trials.... The results unveiled during plenary sessio...0 /- Sahajanand Medical Technologies,...nd manufacturer of,drug-eluting stents, welcomed t... nine months results of PAINT trial (PercutAneous ...
(Date:5/20/2008)...ected in second half of 2008 --,-- Presentation at...ence on, May 21st canceled; webcast of corporate ...holder Meeting on May 22nd at 9:30 a.m. PT --, SA...osciences, Inc.,(Nasdaq: RDEA ) today announced t...en-activated ERK kinase (MEK) inhibitor, RDEA119, ...
(Date:5/20/2008)...rstCall/ -- An interim analysis of a,study present... (DDW),Conference found that, among patients at in...n annual fecal immunochemical (FIT) test, detectio... months earlier than would,have occurred during th...Detection of precancerous lesions in this group oc...
(Date:5/20/2008)...re-FirstCall/ -- BioMarin,Pharmaceutical Inc. (Nas...patient has initiated treatment in the Phase 1 cli...ylalanine ammonia lyase) for the treatment of,phen...de enrollment in the,fourth quarter of 2008., "We...pe to address the,entire spectrum of PKU patients ...
Breaking Medicine Technology:Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 2Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 4Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 2Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 3Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 4Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds 5BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 2BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU 3NSF awards Williams funding for high speed imaging faciltity 1569 1NSF awards Williams funding for high speed imaging faciltity 1569 2Why the switch stays on 1567 1Why the switch stays on 1567 2Why the switch stays on 1567 3Ireland Cancer Center researchers advance stem cell gene therapy 1565 1Ireland Cancer Center researchers advance stem cell gene therapy 1565 2Ireland Cancer Center researchers advance stem cell gene therapy 1565 3Light and sound the way forward for better medical imaging 8122 1Light and sound the way forward for better medical imaging 8122 2
..., 2007--A cervical cancer vaccine has shown 90%,ef...ncerous lesions,associated with the human papillom...de authors of an Article published early Online,an...16 and 18 account for 70% or more,cases of cervica...ic HPV types which can contribute to cervical canc...
...ceed with Development Program for Oral Compounds,t...BUSINESS WIRE)--July 2, 2007--Alkermes, Inc.,(Nasd...ults from a,clinical trial of ALKS 29 in alcohol d...pany plans to move forward with its,development pr...,dependence. ALKS 29 is a combination of two agent...
Other Medicine Technology:Vaccine Can Prevent Cervical Cancer and Precancerous Lesions 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 4
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...i and his team from Wake Forest University Baptist... brain tumor – glioblastoma multiforme. The scient... protein in the brain cells were responsible for s...in the Journal Molecular Cancer Research. Glioblas...
... most common cancers occurring in humans. A clinic... of Eloxatin drug with other chemotherapeutic canc... better prognosis and reduced recurrence in these ...y has proved a combination of Eloxatin with chemot...
... by Dr. Martine Roussel of the St. Jude Children’s...medulloblastoma, the most common malignant brain t...tomas are malignant tumors that are formed by cell... words by poorly developed brain cells. These tumo...
...ugh research scientists have for the first time b...ab into a type of cell that can give rise to organ...rtant advancement will help scientists to use stem...organs. The embryonic stem cells is almost like a ...
Other Medicine News:Health News:Protein Markers for Identification of Brain Tumor 2Health News:Stem cells Can Generate Organs In Labs 2
Unique product designed for LASIK surgery and other types of refractive surgery. Designed to irrigate the corneal interface and/or stromal bed. Flattened tip provides easy insertion under the flap an
Unique product designed for LASIK surgery and other types of refractive surgery. Designed to irrigate the corneal interface and/or stromal bed. Flattened tip provides easy insertion under the flap an
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 20G x 7.8in (.90 x 22mm).
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)
Medicine Products: